Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1

Active, not recruiting

Conditions: Colon Cancer
Resected Stage

Interventions: Drug: Cetuximab
Drug: Expanded CB-NK cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2021-09-10

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05040568

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1

Recruiting

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human

Interventions: Drug: IL-2 (Aldesleukin)
Drug: Cyclophosphamide
Biological: KK-LC-1 TCR
Drug: Fludarabine

First Posted Date: 2021-09-05

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05035407

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Adult T-Cell Leukemia/Lymphoma
Aplastic Anemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia
Hematopoietic and Lymphatic System Neoplasm
Hodgkin Lymphoma

Interventions: Drug: Fludarabine
Radiation: Total-Body Irradiation
Procedure: Donor Lymphocyte Infusion
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Procedure: Hematopoietic Cell Transplantation
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Melphalan
Procedure: Diagnostic Imaging
Procedure: Biospecimen Collection

First Posted Date: 2021-09-02

Last Posted Date: 2024-10-14

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 63

Registration Number: NCT05031897

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent Adult Lymphoblastic Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Recurrent T Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Filgrastim-sndz
Drug: Leucovorin
Drug: Mercaptopurine
Drug: Mesna
Drug: Methotrexate
Biological: Pegfilgrastim
Drug: Prednisone
Biological: Rituximab
Biological: Tagraxofusp-erzs
Drug: Vincristine

First Posted Date: 2021-09-02

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT05032183

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
Breast Neoplasm
Breast Cancer Invasive
Breast Cancer Female
Breast Cancer Stage II
Breast Cancer Stage III
Hormone Receptor-positive Breast Cancer
HER2-positive Breast Cancer
Triple Negative Breast Neoplasms
Estrogen Receptor-positive Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Doxorubicin
Drug: Carboplatin
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Cyclophosphamide
Drug: Pembrolizumab
Drug: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

First Posted Date: 2021-08-25

Last Posted Date: 2024-01-16

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 185

Registration Number: NCT05020860

Locations: 🇺🇸
Harris Health System - Smith Clinic, Houston, Texas, United States
🇺🇸
O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States

TriPRIL CAR T Cells in Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Multiple Myeloma

Interventions: Drug: TriPRIL CAR T Cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2021-08-25

Last Posted Date: 2024-04-29

Lead Sponsor: Marcela V. Maus, M.D.,Ph.D.

Target Recruit Count: 18

Registration Number: NCT05020444

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma

Interventions: Biological: Pembrolizumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Bleomycin
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2021-08-17

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 146

Registration Number: NCT05008224

Locations: 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸
Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸
Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States

and more 45 locations

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Non-hodgkin Lymphoma
Plasma Cell Myeloma
Leukemia, Myeloid, Acute
Leukemia, Lymphoblastic, Acute, L2
Myelodysplastic Syndromes
Leukemia, Lymphoblastic, Acute, L1

Interventions: Drug: Venetoclax
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-08-13

Last Posted Date: 2023-08-01

Lead Sponsor: Melbourne Health

Target Recruit Count: 18

Registration Number: NCT05005299

Locations: 🇦🇺
Melbourne Health, Melbourne, Victoria, Australia

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Hepatocellular Cancer
Metastatic Hepatocellular Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: CAR-T cell
Drug: Fludarabine

First Posted Date: 2021-08-13

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT05003895

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-605
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-08-11

Last Posted Date: 2024-06-28

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 6

Registration Number: NCT05000450

Locations: 🇺🇸
St. David's South Austin Medical Center, Austin, Texas, United States
🇺🇸
Sarah Cannon/Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy